Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Tibet Rhodiola Pharmaceutical Holding Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥310 Mil. Tibet Rhodiola Pharmaceutical Holding Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-10 Mil.
Tibet Rhodiola Pharmaceutical Holding Co's interest coverage for the quarter that ended in Mar. 2026 was 30.51.
The higher the ratio, the stronger the company's financial strength is.
SHSE:600211'
s Interest Coverage Range Over the Past 10 Years
Min: 14.23 Med: 113.04 Max: 1172.01
Current: 41.5
SHSE:600211's Interest Coverage is ranked better than 69.43% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs SHSE:600211: 41.50
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Tibet Rhodiola Pharmaceutical Holding Co Interest Coverage Related Terms
Tibet Rhodiola Pharmaceutical Holding Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Tibet Rhodiola Pharmaceutical Holding Co Interest Coverage Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
SHSE:600211 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co Interest Coverage vs Drug Manufacturers Industry
Tibet Rhodiola Pharmaceutical Holding Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Interest Coverage of 30.51 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is 73% below median its historical median of 113.04. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's Interest Coverage has ranged from 14.23 to 1,172.01. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #210 out of 687 companies in the Drug Manufacturers industry, placing it in the top 30.6%.
Is Tibet Rhodiola Pharmaceutical Holding Co's Interest Coverage too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Interest Coverage of 30.51 is 73% below median its 10-year median of 113.04. Over the past 10 years, this metric has ranged from a low of 14.23 to a high of 1,172.01. The Drug Manufacturers industry median Interest Coverage is 12.75. Tibet Rhodiola Pharmaceutical Holding Co's value of 30.51 is 139.3% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #210 out of 687 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #210 out of 687 companies for Interest Coverage. This puts Tibet Rhodiola Pharmaceutical Holding Co in the upper half of its industry. The industry median Interest Coverage is 12.75. Tibet Rhodiola Pharmaceutical Holding Co's value of 30.51 is 139.3% above this benchmark. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own Interest Coverage has ranged from 14.23 to 1,172.01 over the past decade. While the company's 10-year median is 113.04 vs. the industry median of 12.75, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current Interest Coverage of 30.51 is 139.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current Interest Coverage is 30.51, which is 73% below median its own 10-year median of 113.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥40.53, compared to a current price of ¥39.30 — trading 3% below its estimated fair value. The current Interest Coverage is 30.51, which is 73% below median its 10-year median of 113.04 and 139.3% above the Drug Manufacturers industry median of 12.75. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Interest Coverage is 30.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Interest Coverage: 30.51 (73% below median its 10-year median of 113.04)
GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
Industry Position: 139.3% above the Drug Manufacturers median (#210 of 687)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co Business Description
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score
Get the complete analysis for SHSE:600211
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
